Summary
Becton Dickinson & Co. (BDX) reported solid revenue growth for the third quarter of fiscal year 2023, with total revenues reaching $4.878 billion, a 5.1% increase year-over-year. This growth was driven by broad-based performance across its Medical, Life Sciences, and Interventional segments, with particular strength noted in areas like pharmacy automation and pharmaceutical systems. Despite revenue gains, operating income from continuing operations saw a slight decrease to $549 million from $537 million in the prior year's quarter, and net income applicable to common shareholders was $392 million compared to $338 million. The company's diluted EPS from continuing operations increased to $1.36. The company continues to manage its operational costs effectively and returned significant value to shareholders through dividends. BDX also made progress on strategic initiatives, including the sale of its Surgical Instrumentation platform, highlighting a focus on portfolio optimization.
Financial Highlights
54 data points| Revenue | $4.88B |
| Cost of Revenue | $2.78B |
| Gross Profit | $2.10B |
| R&D Expenses | $306.00M |
| SG&A Expenses | $1.19B |
| Operating Expenses | $4.33B |
| Operating Income | $549.00M |
| Interest Expense | $119.00M |
| Net Income | $407.00M |
| EPS (Basic) | $1.37 |
| EPS (Diluted) | $1.36 |
| Shares Outstanding (Basic) | 286.32M |
| Shares Outstanding (Diluted) | 287.94M |
Key Highlights
- 1Total revenues increased by 5.1% to $4.878 billion for the three months ended June 30, 2023, compared to $4.641 billion in the prior year's quarter.
- 2Net income from continuing operations was $407 million, or $1.36 per diluted share, compared to $390 million, or $1.28 per diluted share, in the prior year.
- 3The Medical segment showed robust revenue growth of 11.1%, driven by Medication Management Solutions and Pharmaceutical Systems, partly due to the acquisition of Parata Systems.
- 4Life Sciences segment revenues decreased by 6.3% primarily due to a significant decline in COVID-19 testing-related revenues.
- 5Interventional segment revenues grew by 6.7%, supported by strong performance in Surgery and Urology and Critical Care.
- 6The company paid $849 million in cash dividends during the first nine months of fiscal year 2023.
- 7BDX completed the sale of its Surgical Instrumentation platform for approximately $540 million, with assets held for sale totaling $271 million at June 30, 2023.